FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013808220> ?p ?o ?g. }

• W2013808220 endingPage "913" @default.
• W2013808220 startingPage "913" @default.
• W2013808220 abstract "Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory disease associated with joint destruction. Tocilizumab (TCZ) is a humanized monoclonal anti-interleukin-6 receptor antibody that was initially developed for use as an intravenous (IV) infusion. Previous studies have shown that TCZ-IV is an important treatment option in patients with moderate-to-severe RA. A subcutaneous (SC) formulation of 162 mg TCZ that was recently developed and approved provides an additional treatment option for RA patients. In the present review, we provide an update on the efficacy and safety of TCZ-SC, compared with TCZ-IV. The TCZ-SC doses of 162 mg every 2 weeks (q2w) or weekly (qw) were selected based on pharmacokinetic and pharmacodynamic studies. Both TCZ-SC q2w and qw regimens showed equivalent effects to TCZ-IV in most patients; however, the TCZ-SC qw regimen consistently showed a more rapid effect in terms of C-reactive protein normalization. Randomized controlled studies showed that TCZ-SC monotherapy or combined with disease-modifying antirheumatic drugs demonstrated comparable efficacy to TCZ-IV in patients who were both biologic-naïve and refractory to tumor necrosis factor inhibitors. TCZ-SC at both qw and q2w were generally well-tolerated for up to 24 weeks. There was a low rate of withdrawal due to adverse events, and their incidence was comparable with that seen with TCZ-IV. An injection site reaction was seen in approximately 10% of patients who received the subcutaneous formulation. In conclusion, although clinical results are still limited, the currently available evidence suggests that TCZ-SC is a promising treatment for moderate-to-severe RA, both as monotherapy and combination therapy. More data is needed to determine the optimal dosing schedule." @default.
• W2013808220 created "2016-06-24" @default.
• W2013808220 creator A5002669324 @default.
• W2013808220 creator A5011966088 @default.
• W2013808220 creator A5039553170 @default.
• W2013808220 creator A5090740323 @default.
• W2013808220 date "2014-07-01" @default.
• W2013808220 modified "2023-10-16" @default.
• W2013808220 title "Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis &ndash; focus on subcutaneous tocilizumab" @default.
• W2013808220 cites W1517879760 @default.
• W2013808220 cites W1608734376 @default.
• W2013808220 cites W1965350798 @default.
• W2013808220 cites W1984842785 @default.
• W2013808220 cites W1988108320 @default.
• W2013808220 cites W2001015097 @default.
• W2013808220 cites W2003207115 @default.
• W2013808220 cites W2011138201 @default.
• W2013808220 cites W2011709831 @default.
• W2013808220 cites W2023729916 @default.
• W2013808220 cites W2028097373 @default.
• W2013808220 cites W2043541492 @default.
• W2013808220 cites W2054059257 @default.
• W2013808220 cites W2054789510 @default.
• W2013808220 cites W2054839097 @default.
• W2013808220 cites W2055563250 @default.
• W2013808220 cites W2063485775 @default.
• W2013808220 cites W2069473482 @default.
• W2013808220 cites W2081559577 @default.
• W2013808220 cites W2096862304 @default.
• W2013808220 cites W2097874407 @default.
• W2013808220 cites W2102207725 @default.
• W2013808220 cites W2113398090 @default.
• W2013808220 cites W2114308202 @default.
• W2013808220 cites W2117549257 @default.
• W2013808220 cites W2125212735 @default.
• W2013808220 cites W2128260735 @default.
• W2013808220 cites W2132810505 @default.
• W2013808220 cites W2133038175 @default.
• W2013808220 cites W2134714663 @default.
• W2013808220 cites W2139339400 @default.
• W2013808220 cites W2143875454 @default.
• W2013808220 cites W2148843297 @default.
• W2013808220 cites W2150952126 @default.
• W2013808220 cites W2155109530 @default.
• W2013808220 cites W2318541623 @default.
• W2013808220 cites W2412254290 @default.
• W2013808220 cites W2600516270 @default.
• W2013808220 doi "https://doi.org/10.2147/dddt.s52099" @default.
• W2013808220 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4094568" @default.
• W2013808220 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25045250" @default.
• W2013808220 hasPublicationYear "2014" @default.
• W2013808220 type Work @default.
• W2013808220 sameAs 2013808220 @default.
• W2013808220 citedByCount "15" @default.
• W2013808220 countsByYear W20138082202014 @default.
• W2013808220 countsByYear W20138082202015 @default.
• W2013808220 countsByYear W20138082202016 @default.
• W2013808220 countsByYear W20138082202017 @default.
• W2013808220 countsByYear W20138082202018 @default.
• W2013808220 countsByYear W20138082202019 @default.
• W2013808220 countsByYear W20138082202020 @default.
• W2013808220 countsByYear W20138082202021 @default.
• W2013808220 countsByYear W20138082202022 @default.
• W2013808220 crossrefType "journal-article" @default.
• W2013808220 hasAuthorship W2013808220A5002669324 @default.
• W2013808220 hasAuthorship W2013808220A5011966088 @default.
• W2013808220 hasAuthorship W2013808220A5039553170 @default.
• W2013808220 hasAuthorship W2013808220A5090740323 @default.
• W2013808220 hasBestOaLocation W20138082201 @default.
• W2013808220 hasConcept C111113717 @default.
• W2013808220 hasConcept C112705442 @default.
• W2013808220 hasConcept C126322002 @default.
• W2013808220 hasConcept C197934379 @default.
• W2013808220 hasConcept C2776390293 @default.
• W2013808220 hasConcept C2777178219 @default.
• W2013808220 hasConcept C2777575956 @default.
• W2013808220 hasConcept C2781413609 @default.
• W2013808220 hasConcept C71924100 @default.
• W2013808220 hasConcept C90924648 @default.
• W2013808220 hasConcept C98274493 @default.
• W2013808220 hasConceptScore W2013808220C111113717 @default.
• W2013808220 hasConceptScore W2013808220C112705442 @default.
• W2013808220 hasConceptScore W2013808220C126322002 @default.
• W2013808220 hasConceptScore W2013808220C197934379 @default.
• W2013808220 hasConceptScore W2013808220C2776390293 @default.
• W2013808220 hasConceptScore W2013808220C2777178219 @default.
• W2013808220 hasConceptScore W2013808220C2777575956 @default.
• W2013808220 hasConceptScore W2013808220C2781413609 @default.
• W2013808220 hasConceptScore W2013808220C71924100 @default.
• W2013808220 hasConceptScore W2013808220C90924648 @default.
• W2013808220 hasConceptScore W2013808220C98274493 @default.
• W2013808220 hasLocation W20138082201 @default.
• W2013808220 hasLocation W20138082202 @default.
• W2013808220 hasLocation W20138082203 @default.
• W2013808220 hasLocation W20138082204 @default.
• W2013808220 hasOpenAccess W2013808220 @default.
• W2013808220 hasPrimaryLocation W20138082201 @default.
• W2013808220 hasRelatedWork W1758514097 @default.

• next